Clinical characteristics of primary cutaneous and subcutaneous Ewing sarcoma
- PMID: 37093679
- DOI: 10.1093/jjco/hyad031
Clinical characteristics of primary cutaneous and subcutaneous Ewing sarcoma
Abstract
Objective: Given the rarity of cutaneous/subcutaneous Ewing sarcoma, their clinical characteristics remain poorly understood. In this study, we aimed to analyse the clinical characteristics of patients with cutaneous/subcutaneous Ewing sarcoma and review the treatment strategy.
Methods: We reviewed the clinical data of 154 patients with Ewing sarcoma who were treated at our hospital between 2005 and 2019. Amongst these patients, 21 patients with cutaneous/subcutaneous Ewing sarcoma were analysed. As a basic strategy, patients with localized disease received intensive chemotherapy (vincristine-doxorubicin-cyclophosphamide/ifosfamide-etoposide), followed by definitive surgery with or without radiotherapy. In total, 15 patients underwent pre-diagnostic resection with macroscopic residue (seven patients) or non-macroscopic residue (eight patients) before intensive chemotherapy.
Results: The median tumour length of the measurable lesions was 3.2 cm, and the ratio of metastasis was significantly lower than the Ewing sarcoma of other anatomical sites (10% vs. 37%, P = 0.013). Despite the pre-diagnostic resection, local recurrence after additional resection and/or adjuvant radiotherapy did not occur in any of the patients with localized disease. Overall survival was significantly higher in patients with cutaneous/subcutaneous Ewing sarcoma than in patients with Ewing sarcoma of other anatomical sites (hazard ratio = 0.33, P = 0.013). The event-free survival rate of cutaneous/subcutaneous Ewing sarcoma was also superior to that of Ewing sarcoma of other anatomical sites (hazard ratio = 0.35, P = 0.01).
Conclusions: Patients with cutaneous/subcutaneous Ewing sarcoma may have better prognosis than those with Ewing sarcoma at other anatomical sites. Although pre-diagnostic resection without appropriate investigations is not recommended, local control may be recovered by using a combination of additional resection, chemotherapy and radiotherapy.
Keywords: Ewing sarcoma; chemotherapy; radiation; skin; subcutaneous; surgery.
© The Author(s) 2023. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Similar articles
-
Feasibility of Treating Adults with Ewing or Ewing-Like Sarcoma with Interval-Compressed Vincristine, Doxorubicin, and Cyclophosphamide Alternating with Ifosfamide and Etoposide.Oncologist. 2020 Feb;25(2):150-155. doi: 10.1634/theoncologist.2019-0532. Epub 2019 Oct 2. Oncologist. 2020. PMID: 32043790 Free PMC article.
-
Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.Lancet. 2022 Oct 29;400(10362):1513-1521. doi: 10.1016/S0140-6736(22)01790-1. Lancet. 2022. PMID: 36522207 Clinical Trial.
-
Outcomes of extraskeletal vs. skeletal Ewing sarcoma patients treated with standard chemotherapy protocol.Clin Transl Oncol. 2020 Jun;22(6):878-883. doi: 10.1007/s12094-019-02202-y. Epub 2019 Aug 19. Clin Transl Oncol. 2020. PMID: 31429039
-
Primary cutaneous/subcutaneous Ewings sarcoma.Bull Cancer. 2025 Jun;112(6):611-618. doi: 10.1016/j.bulcan.2023.10.011. Epub 2025 Mar 11. Bull Cancer. 2025. PMID: 40074591 Review.
-
Effectiveness and safety of primary prophylaxis with G-CSF for patients with Ewing sarcomas: a systematic review for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology.Int J Clin Oncol. 2024 Aug;29(8):1081-1087. doi: 10.1007/s10147-024-02572-6. Epub 2024 Jun 21. Int J Clin Oncol. 2024. PMID: 38904887
Cited by
-
Adequate Diagnostic and Therapeutic Management Practices in Dermatofibrosarcoma Protuberans.Sage Open Pediatr. 2025 Mar 23;12:30502225251325626. doi: 10.1177/30502225251325626. eCollection 2025 Jan-Dec. Sage Open Pediatr. 2025. PMID: 40612178 Free PMC article. No abstract available.
-
LOXHD1 is an oncofusion-regulated antigen of ewing sarcoma.Sci Rep. 2025 Apr 15;15(1):13007. doi: 10.1038/s41598-025-96877-9. Sci Rep. 2025. PMID: 40234527 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials